slno,preds
0,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key details:

1. **Tumor Characteristics**:
   - There are two distinct adenocarcinomas: 
     - A 1 cm solid predominant adenocarcinoma in the lingula.
     - A 3.5 cm micropapillary predominant adenocarcinoma in the left lower lobe.
   - Both tumors have free margins, indicating that the surgical resection was complete with no residual tumor at the margins.

2. **Lymph Node Involvement**:
   - No lymph node metastasis was identified, which is a favorable prognostic factor.

3. **Molecular Findings**:
   - A positive KRAS mutation is present, which is generally associated with a poorer prognosis and potential resistance to certain therapies.
   - No EGFR mutations were detected, which limits the use of targeted therapies that are effective in EGFR-mutated cancers.

4. **Additional Findings**:
   - Emphysema is noted, which may affect overall lung function but is not directly related to cancer prognosis.
   - The tumors are morphologically distinct, suggesting they may be separate primary cancers rather than metastatic spread from one to the other.

5. **Prognostic Considerations**:
   - The absence of lymph node metastasis and clear surgical margins are positive indicators for survival.
   - The presence of a KRAS mutation is a negative prognostic factor, but it does not necessarily preclude survival beyond 2.48 years, especially in the absence of other high-risk features like lymph node involvement or distant metastasis.

Given these considerations, while the KRAS mutation suggests a poorer prognosis, the overall findings (small tumor size, no lymph node involvement, clear margins) suggest a reasonable likelihood of survival beyond 2.48 years.

Answer - {""Survival"": ""True""}"
1,"The pathology report provides the following key details:

1. **Tumor Characteristics**: The adenocarcinoma is moderately differentiated and measures 2.0 x 2.0 x 1.6 cm. This indicates a relatively small tumor size.

2. **Pleural Invasion**: There is focal pleural invasion, which suggests some level of aggressiveness, but it is not extensive.

3. **Lymphovascular Space Invasion**: There is no lymphovascular space invasion, which is a positive prognostic factor as it indicates the cancer has not spread through the lymphatic or vascular systems.

4. **Lymph Node Status**: Multiple lymph nodes were biopsied and all were negative for neoplasm, indicating no lymph node involvement (N0).

5. **Tumor Staging**: The tumor is staged as T2N0. T2 indicates a tumor size greater than 3 cm but less than 5 cm, or a tumor with certain features such as pleural invasion. N0 indicates no regional lymph node metastasis.

Based on these factors, the prognosis appears relatively favorable. The absence of lymph node involvement and lymphovascular invasion, along with the moderate differentiation of the tumor, suggest a lower risk of aggressive disease progression. Although there is focal pleural invasion, the overall staging of T2N0 is associated with a better prognosis compared to more advanced stages.

Therefore, it is reasonable to conclude that the patient has a good chance of survival beyond 2.48 years.

Answer - {""Survival"": ""True""}"
2,"The pathology report provides the following key details:

1. **Tumor Characteristics**: The adenocarcinoma is well-differentiated and minimally invasive, with a lepidic pattern. The tumor size is 2.8 cm.

2. **Surgical Margins**: The surgical margins are negative, indicating that the tumor was completely resected.

3. **Invasion**: There is no evidence of lymphovascular invasion or visceral pleura invasion.

4. **Lymph Node Status**: Lymph node examinations from various sites showed no malignancy, indicating no lymph node involvement.

5. **Staging**: The cancer is staged as pT1b, pN1. This indicates a small tumor size (T1b) with minimal lymph node involvement (N1).

Given these factors, the prognosis is generally favorable. The tumor is small, well-differentiated, and minimally invasive, with no lymphovascular or pleural invasion. The negative surgical margins and absence of lymph node malignancy further support a positive outlook. Although there is minimal lymph node involvement (pN1), the overall characteristics suggest a good chance of survival beyond 2.48 years.

Answer - {""Survival"": ""True""}"
3,"The pathology report describes a moderately-poorly differentiated adenocarcinoma in the left upper lobe of the lung. The tumor measures 2.5 x 2.0 cm, which is relatively small in size. However, a significant concern is the involvement of ten out of twelve examined lymph nodes with metastatic carcinoma, including the subcarinal lymph node. This indicates a substantial spread of cancer to the lymphatic system, which is a poor prognostic factor.

Additionally, there is extensive lymphovascular invasion noted within the lung tissue. Lymphovascular invasion is another negative prognostic indicator as it suggests that cancer cells have invaded the blood vessels and lymphatics, increasing the risk of further metastasis.

The surgical margins are negative for tumor, which is a positive aspect, indicating that the tumor was completely resected. However, given the extensive lymph node involvement and lymphovascular invasion, the overall prognosis is poor.

Considering these factors, the likelihood of survival after 2.48 years is low.

Answer - {""Survival"": ""False""}"
4,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key findings:

1. **Tumor Characteristics**: The patient has an invasive poorly differentiated adenocarcinoma in the left upper lobe of the lung, measuring 2.7 cm. Poor differentiation generally indicates a more aggressive tumor, which can negatively impact prognosis.

2. **Visceral Pleura Invasion**: The tumor invades the visceral pleura. Pleural invasion is associated with a higher stage and can be a negative prognostic factor.

3. **Intratumoral Large Vessel Invasion**: The presence of large vessel invasion is a significant adverse prognostic factor, as it suggests a higher likelihood of metastasis and aggressive disease behavior.

4. **Lymph Node Status**: The level 5 lymph node resection revealed anthracotic lymph nodes that were negative for metastatic carcinoma. The absence of lymph node metastasis is a positive prognostic factor.

5. **Staging**: The tumor is staged as pT2a, which indicates a tumor size greater than 3 cm but less than or equal to 5 cm, with invasion into the visceral pleura but no lymph node involvement (N0) or distant metastasis (M0). This stage suggests localized disease, which is generally more favorable than advanced stages.

6. **Parenchymal Margin**: The tumor has a parenchymal margin of 8 mm, which is a clear margin and generally considered adequate, reducing the likelihood of local recurrence.

7. **No Distant Metastasis**: The absence of distant metastasis is a positive factor for survival.

Considering these factors, the presence of poorly differentiated histology and large vessel invasion are significant negative prognostic indicators. However, the absence of lymph node involvement and distant metastasis, along with clear surgical margins, are positive factors. The balance of these factors suggests a guarded prognosis, but not definitively poor enough to conclude non-survival within 2.48 years.

Answer - {""Survival"": ""True""}"
5,"The pathology report provides the following key information:

1. **Diagnosis**: Invasive mucinous adenocarcinoma in the right upper lobe of the lung.
2. **Tumor Size**: 2.5 cm.
3. **Margins**: Clear margins with no residual tumor after completion lobectomy.
4. **Lymph Nodes**: All examined lymph nodes (levels 4, 7, and 10) are negative for carcinoma, indicating no regional lymph node metastasis.
5. **Molecular Studies**: Positive KRAS mutation (p.G12C) and no EGFR mutations detected.

**Analysis**:
- The tumor is relatively small (2.5 cm) and has been completely resected with clear margins, which is a favorable factor.
- The absence of lymph node metastasis is a positive prognostic indicator, as it suggests localized disease without regional spread.
- The presence of a KRAS mutation (p.G12C) is associated with a poorer prognosis and potential resistance to certain therapies, which is a negative factor.
- However, the overall pathology report suggests that the disease is localized and has been surgically addressed effectively.

**Conclusion**:
Despite the presence of a KRAS mutation, the localized nature of the disease, clear surgical margins, and absence of lymph node involvement suggest a favorable prognosis for survival beyond 2.48 years.

Answer - {""Survival"": ""True""}"
6,"The pathology report provides the following key information:

1. **Invasive Grade 3 Adenocarcinoma**: This indicates a high-grade tumor, which generally suggests a more aggressive cancer with a poorer prognosis.

2. **Tumor Size and Margins**: The tumor measures 5 x 4 x 3 cm, and the bronchial margins are negative, meaning the tumor has been completely excised from the bronchial margins.

3. **Lymph Node Involvement**: One of six intrapulmonary peribronchial lymph nodes tested positive for metastatic adenocarcinoma. This indicates regional lymph node involvement, which is a negative prognostic factor.

4. **Necrotizing Granuloma and Granulomatous Lymphadenitis**: The presence of necrotizing granuloma in the right upper lobe and necrotizing granulomatous lymphadenitis in multiple mediastinal lymph nodes, which are negative for tumor, suggests an inflammatory or infectious process rather than cancer spread.

5. **Special Stains for Microorganisms**: These were negative, indicating no infectious organisms were identified in the subcarinal lymph nodes.

Considering these factors:

- The presence of metastatic adenocarcinoma in one lymph node suggests a more advanced stage of cancer, which typically correlates with a poorer prognosis.
- The high-grade nature of the tumor (Grade 3) also suggests a more aggressive disease.
- However, the negative bronchial margins are a positive factor, indicating that the tumor was completely excised in that area.

Given the combination of high-grade tumor and lymph node involvement, the prognosis is likely poor, and survival beyond 2.48 years is uncertain.

Answer - {""Survival"": ""False""}"
7,"1. **Tumor Differentiation and Size**: The tumor is moderately differentiated, which generally indicates a better prognosis than poorly differentiated tumors. The size of the tumor is 2.3 cm, which is relatively small.

2. **Tumor Margins and Invasion**: The carcinoma extends to within 1 mm of the staple line but does not invade the visceral pleura. This suggests that the tumor is localized and has not spread beyond its original site.

3. **Lymph Node Involvement**: No metastatic carcinoma was identified in the examined lymph nodes, indicating that the cancer has not spread to these areas.

4. **Staging**: The final staging is pT1b N0. This indicates a small tumor (T1b) with no lymph node involvement (N0), which is generally associated with a favorable prognosis.

5. **Recommendation**: Clinical correlation and follow-up are recommended, which is standard practice to monitor for any changes or recurrence.

Based on these factors, the prognosis appears favorable, and the likelihood of survival after 2.48 years is high.

Answer - {""Survival"": ""True""}"
8,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key findings:

1. **Tumor Differentiation**: The adenocarcinoma is moderately differentiated, which generally indicates an intermediate prognosis compared to well-differentiated (better prognosis) and poorly differentiated (worse prognosis) tumors.

2. **Lymph Node Involvement**: There is metastatic involvement in one of four hilar lymph nodes. Lymph node involvement typically suggests a higher stage of cancer and can negatively impact prognosis. However, involvement in only one lymph node may still allow for a relatively favorable outcome, especially if the disease is otherwise localized.

3. **Surgical Margins**: The surgical margins, including the bronchial resection margin, are negative for carcinoma. This is a positive finding, as it suggests that the tumor was completely resected, reducing the likelihood of local recurrence.

4. **Pleural and Angiolymphatic Invasion**: There is no evidence of pleural involvement or angiolymphatic invasion. The absence of these features is favorable, as their presence would typically indicate a more aggressive disease and a worse prognosis.

5. **Additional Findings**: The presence of hyalinized granulomata in other lymph nodes does not indicate cancer spread and is not directly relevant to the prognosis of the adenocarcinoma.

Considering these factors, the presence of metastatic involvement in one lymph node is a concern, but the absence of pleural and angiolymphatic invasion, along with negative surgical margins, suggests that the cancer may have been effectively managed surgically. Therefore, the patient may have a reasonable chance of survival beyond 2.48 years, although close monitoring and possibly additional treatment may be necessary.

Answer - {""Survival"": ""True""}"
9,"The pathology report describes an invasive well-differentiated adenocarcinoma with a predominant bronchiolo-alveolar carcinoma component in the left lower lobe. The tumor measures approximately 50 x 60 x 45 mm. Key points to consider for survival prognosis include:

1. **Differentiation**: The tumor is well-differentiated, which generally indicates a better prognosis compared to poorly differentiated tumors.

2. **Invasion**: There is no evidence of vascular or perineural invasion, which is a positive factor as these types of invasions can lead to worse outcomes.

3. **Metastasis**: There are no metastases to hilar lymph nodes, suggesting that the cancer has not spread to these regional lymph nodes, which is a favorable sign.

4. **Pleural Involvement**: Although the tumor closely abuts the pleural surface, confirmatory stains suggest that the pleura is likely not involved. Lack of pleural invasion is a positive prognostic factor.

5. **Additional Findings**: The separate specimen from the back shows a lipoma, which is benign and not related to the malignancy.

Considering these factors, the absence of lymph node metastasis, lack of vascular or perineural invasion, and likely non-involvement of the pleura suggest a relatively favorable prognosis. Therefore, it is reasonable to conclude that the patient is likely to survive beyond 2.48 years.

Answer - {""Survival"": ""True""}"
10,"1. **Tumor Characteristics**: The tumor is a poorly differentiated adenocarcinoma, which generally indicates a more aggressive cancer with a worse prognosis compared to well-differentiated tumors.

2. **Size and Invasion**: The tumor measures 3 x 3 x 3 cm and has invaded the visceral pleura. Pleural invasion is a negative prognostic factor as it suggests a more advanced local disease.

3. **Lymph Node Metastasis**: There is metastasis in 1 out of 1 examined lymph node. The presence of lymph node metastasis is a significant negative prognostic factor, indicating that the cancer has started to spread beyond the primary site.

4. **Immunohistochemical Staining**: The tumor is positive for CD15, CK7, TTF1, and CEA, and negative for CK20 and CDX2. These markers are consistent with a primary lung adenocarcinoma, but they do not directly impact the prognosis in terms of survival.

5. **Overall Staging and Prognosis**: The combination of poorly differentiated histology, pleural invasion, and lymph node metastasis suggests a more advanced stage of cancer, likely stage III or higher, which is associated with a lower survival rate at 2.48 years.

Based on these factors, the prognosis is poor, and the likelihood of survival after 2.48 years is low.

Answer - {""Survival"": ""False""}"
11,"The pathology report provides the following key details:

1. **Tumor Size and Type**: The tumor is located in the left lower lobe of the lung, measuring 4.0 x 3.5 x 2.0 cm, and is diagnosed as adenocarcinoma of mixed subtype, predominantly papillary.

2. **Visceral Pleura Infiltration**: There is infiltration of the visceral pleura, which can be a concerning feature as it indicates some level of local invasion.

3. **Tumor Classification**: The tumor is classified as pT2, which generally indicates a tumor size greater than 3 cm but less than or equal to 5 cm, or a tumor with certain local invasion characteristics.

4. **Lymph Node Involvement**: There is no regional lymph node involvement (0 out of 20 nodes examined), which is a positive prognostic factor.

5. **Distant Metastasis Status**: The distant metastasis status is unknown (pMx), which means there is no information on whether the cancer has spread to distant sites.

6. **Tumor Grade**: The tumor is graded as G2, indicating moderate differentiation. This suggests that the tumor cells are somewhat abnormal but not highly aggressive.

Considering these factors:

- The absence of lymph node involvement is a favorable prognostic factor.
- The moderate differentiation (G2) suggests a less aggressive tumor compared to poorly differentiated ones.
- The unknown status of distant metastasis (pMx) introduces some uncertainty, but without evidence of metastasis, the prognosis is generally better.
- The infiltration of the visceral pleura is a concern, but it is not definitive for poor survival without additional negative factors like lymph node involvement or confirmed distant metastasis.

Based on the information provided, the patient has a reasonable chance of survival beyond 2.48 years, assuming no distant metastasis is present.

Answer - {""Survival"": ""True""}"
12,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key findings:

1. **Tumor Characteristics**: The tumor is a moderately differentiated adenocarcinoma measuring 2.7 cm. Moderate differentiation generally indicates an intermediate prognosis compared to well-differentiated (better prognosis) and poorly differentiated (worse prognosis) tumors.

2. **Invasion and Margins**: There is no angiolymphatic invasion or pleural involvement, and the bronchial margin is negative. These are favorable findings, as they suggest the tumor has not spread extensively within the lung or to surrounding structures.

3. **Lymph Node Involvement**: Metastatic adenocarcinoma was found in 1 out of 4 peribronchial lymph nodes. However, no metastatic carcinoma was identified in the R4 and station 11 lymph nodes. The presence of metastasis in one lymph node indicates some regional spread, which can affect prognosis, but the absence of metastasis in other examined lymph nodes is a positive sign.

4. **Surgical Margins**: The surgical margins are negative for tumor involvement, indicating that the tumor was likely completely resected, which is a positive prognostic factor.

5. **Additional Lesions**: No additional lesions were noted in the surrounding lung tissue, suggesting no further local spread.

Considering these factors, the presence of metastasis in one lymph node suggests a stage that may be associated with a moderate risk of recurrence or progression. However, the absence of extensive lymph node involvement, negative surgical margins, and lack of angiolymphatic or pleural invasion are favorable factors that could contribute to a better prognosis.

Based on this analysis, the likelihood of survival after 2.48 years is reasonably favorable, but not guaranteed. However, given the overall positive findings, the patient is more likely to survive beyond 2.48 years.

Answer - {""Survival"": ""True""}"
13,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key details:

1. **Tumor Size and Differentiation**: The tumor is relatively small at 1.2 cm, which is generally favorable for prognosis. However, it is classified as moderately to poorly differentiated, which can indicate a more aggressive tumor behavior.

2. **Surgical Margins**: All surgical margins are free of tumor, which is a positive indicator as it suggests that the tumor has been completely resected.

3. **Visceral Pleura Invasion**: There is focal invasion into the visceral pleura. While this is a negative factor, the extent of invasion is not specified as extensive, which may mitigate its impact on prognosis.

4. **Lymphatic Invasion**: There is a focus suggestive of lymphatic invasion, which can be concerning as it may indicate potential for metastasis. However, no lymph node involvement was detected among the seven examined, which is a positive finding.

5. **Lymph Node Involvement**: The absence of lymph node involvement is a favorable prognostic factor, as lymph node metastasis is often associated with a worse prognosis.

6. **Further Mutation Analysis**: The recommendation for further mutation analysis for EGFR and KRAS suggests that targeted therapy options may be available, which could improve the patient's prognosis if actionable mutations are found.

Considering these factors, the small tumor size, clear surgical margins, and absence of lymph node involvement are positive indicators for survival. The moderately to poorly differentiated grade and focal pleural and lymphatic invasion are negative factors, but they are not definitive for a poor prognosis given the other favorable findings.

Based on this analysis, the likelihood of survival after 2.48 years is more likely to be positive, assuming appropriate follow-up and potential targeted therapies are pursued.

Answer - {""Survival"": ""True""}"
14,"1. **Tumor Characteristics**: The adenocarcinoma is acinar type, grade III, which indicates a poorly differentiated tumor. Poor differentiation is generally associated with a more aggressive cancer and a worse prognosis.

2. **Tumor Size and Invasion**: The tumor measures 4 cm and invades the visceral pleura. Invasion of the visceral pleura can be associated with a higher risk of recurrence and metastasis.

3. **Margins**: The bronchial and vascular margins are negative, which is a positive factor as it suggests that the tumor has been completely resected in those areas.

4. **Lymph Node Involvement**: Metastatic adenocarcinoma was identified in two of four lymph nodes examined. This indicates regional lymph node involvement, which is a significant negative prognostic factor.

5. **Staging**: The cancer is staged as pT2, N2, Mx. The T2 stage indicates a tumor size of more than 3 cm but less than 5 cm, with pleural invasion. N2 indicates metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes, which is associated with a poorer prognosis. Mx means that distant metastasis cannot be assessed, which leaves uncertainty regarding the presence of distant spread.

6. **Overall Prognosis**: The combination of a poorly differentiated tumor, pleural invasion, and N2 lymph node involvement suggests a more advanced disease with a higher risk of recurrence and metastasis. These factors generally correlate with a lower survival rate beyond 2.48 years.

Based on these considerations, the likelihood of survival beyond 2.48 years is low.

Answer - {""Survival"": ""False""}"
15,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key findings:

1. **Tumor Characteristics**: The report describes an invasive moderately differentiated adenocarcinoma measuring 9.2 cm. The size and differentiation level of the tumor are important factors in prognosis. Moderately differentiated tumors generally have a better prognosis than poorly differentiated ones, but the large size (9.2 cm) is concerning.

2. **Invasion**: The tumor has invaded the chest wall, which is a significant factor as it indicates more aggressive behavior and a higher stage of cancer. Chest wall invasion typically corresponds to a higher T stage (pT3 in this case), which can negatively impact survival.

3. **Margins**: The surgical margins are negative for carcinoma, which is a positive finding, indicating that the tumor was likely completely resected, reducing the risk of local recurrence.

4. **Lymph Nodes**: All 19 examined peribronchial lymph nodes are negative for carcinoma, which is a favorable prognostic factor as it suggests no regional lymph node metastasis.

5. **Additional Findings**: Chronic inflammation and emphysematous changes are noted in the non-neoplastic lung tissue, but these findings are not directly related to cancer prognosis.

6. **Pathological Staging**: The tumor is staged as pT3, indicating a large tumor with chest wall invasion but no lymph node involvement (N0) or distant metastasis (M0).

Considering these factors, the absence of lymph node involvement and negative surgical margins are positive indicators. However, the large size of the tumor and chest wall invasion are concerning and suggest a more advanced local disease. While these factors do not definitively predict survival, they suggest a more guarded prognosis.

Based on the information provided, the likelihood of survival after 2.48 years is uncertain but leans towards a more cautious outlook due to the advanced local disease (pT3) despite the absence of lymph node involvement.

Answer - {""Survival"": ""False""}"
16,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key findings:

1. **Diagnosis**: The patient has lung adenocarcinoma, which is a type of non-small cell lung cancer.

2. **Tumor Characteristics**: The primary tumor is moderately differentiated and measures 6.9 cm. There is visceral pleural invasion, which indicates that the tumor has invaded the pleura, a layer covering the lungs.

3. **Lymph Node Involvement**: Metastatic adenocarcinoma was identified in lymph nodes from the left level 9 and two out of five lymph nodes from the left level 11. This indicates regional lymph node involvement.

4. **Lymphangitic Invasion**: The presence of lymphangitic invasion suggests that cancer cells are spreading through the lymphatic system, which can be associated with a more aggressive disease.

5. **No Distant Metastasis**: There is no evidence of distant metastasis, which is a positive factor in terms of prognosis.

Considering these factors:
- The presence of regional lymph node involvement and lymphangitic invasion suggests a more advanced stage of cancer, likely stage III.
- The moderately differentiated nature of the tumor and the absence of distant metastasis are somewhat favorable, but the pleural and lymphatic invasions are concerning.

Given the combination of these factors, the prognosis is guarded, and survival beyond 2.48 years is uncertain. However, the presence of regional lymph node involvement and lymphangitic invasion typically indicates a poorer prognosis.

Therefore, based on the information provided, the likelihood of survival after 2.48 years is more likely to be unfavorable.

Answer - {""Survival"": ""False""}"
17,"The pathology report provided lacks specific diagnostic information about the case, such as the type of tumor, its size, grade, stage, presence of metastasis, or any other relevant pathological findings. Without this critical information, it is impossible to accurately assess the prognosis or survival likelihood of the patient after 2.48 years. The report only mentions administrative details related to the handling of the specimen and does not provide any clinical or pathological data that could be used to make a survival prediction.

Therefore, due to the absence of specific diagnostic information, it is not possible to determine the patient's survival outcome based on the provided report.

Answer - {""Survival"": ""False""}"
18,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key details:

1. **Diagnosis and Tumor Characteristics**:
   - The patient has a well-differentiated papillary non-mucinous adenocarcinoma, which generally indicates a better prognosis compared to poorly differentiated tumors.
   - The tumor measures 50 mm and extends to the visceral pleura but is tumor-free, suggesting no pleural invasion.

2. **Staging**:
   - The tumor is classified as pT2, indicating a tumor size greater than 3 cm but less than or equal to 5 cm, or a tumor that involves the main bronchus or invades the visceral pleura.
   - pN0 indicates no regional lymph node involvement, which is a favorable prognostic factor.
   - pMX indicates that distant metastasis cannot be assessed, but there is no evidence of distant metastasis provided in the report.
   - The overall stage is I B, which is an early stage of lung cancer, typically associated with a higher survival rate.

3. **Resection Margins**:
   - The resection margins are clear of tumor (R0), indicating that the tumor has been completely removed, which is a positive factor for survival.

4. **Additional Findings**:
   - Subpleural scarring and pleural adhesions are noted, but these do not indicate malignancy or affect the prognosis significantly.

Given these factors, the patient has a well-differentiated tumor with no lymph node involvement, no evidence of distant metastasis, and clear resection margins. These are all favorable indicators for survival beyond 2.48 years.

Answer - {""Survival"": ""True""}"
19,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key findings:

1. **Tumor Characteristics**: The report describes a poorly differentiated adenocarcinoma, which generally indicates a more aggressive tumor with a worse prognosis compared to well-differentiated tumors.

2. **Tumor Size and Invasion**: The tumor measures 4.5 cm and shows visceral pleural and lymphovascular invasion. The presence of invasion into the pleura and lymphovascular structures suggests a more advanced and aggressive disease.

3. **Lymph Node Involvement**: Although most excised lymph nodes show no evidence of metastatic carcinoma, one of the six lymph nodes examined contains metastatic carcinoma with extracapsular extension. This indicates that the cancer has spread beyond the primary tumor site, which is a negative prognostic factor.

4. **Staging**: The tumor is staged as pT2aN1MX. The T2a stage indicates a tumor size between 3 and 5 cm with certain invasive characteristics. N1 indicates regional lymph node involvement, which is associated with a higher risk of recurrence and poorer prognosis. MX means that distant metastasis cannot be assessed, leaving uncertainty about the presence of metastasis elsewhere in the body.

Considering these factors, the presence of poorly differentiated adenocarcinoma, lymphovascular invasion, pleural involvement, and lymph node metastasis with extracapsular extension suggests a more aggressive disease with a higher risk of recurrence and poorer prognosis. Therefore, the likelihood of survival after 2.48 years is lower.

Answer - {""Survival"": ""False""}"
20,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, we need to consider several factors typically associated with prognosis in lung cancer:

1. **Tumor Differentiation**: The report describes the tumor as ""poorly differentiated,"" which generally indicates a more aggressive cancer with a potentially worse prognosis compared to well-differentiated tumors.

2. **Tumor Size**: The tumor measures 2.5 x 1.5 x 3 cm. This size is relatively small, which might suggest a better prognosis if the cancer is localized.

3. **Lymph Node Involvement**: The report does not specify whether there is lymph node involvement. The absence of lymph node metastasis is generally associated with a better prognosis.

4. **Invasion and Metastasis**: The report lacks details on invasion into surrounding tissues or distant metastasis. The absence of such information makes it difficult to fully assess the stage and prognosis.

5. **Additional Findings**: There are no additional findings or comments, which limits the ability to assess other potential prognostic factors.

Given the limited information, particularly the lack of details on lymph node involvement and invasion, it is challenging to make a definitive prognosis. However, the small size of the tumor and the absence of reported metastasis or invasion might suggest a potentially favorable outcome, assuming the cancer is localized.

Based on the available information, the likelihood of survival after 2.48 years could be considered more favorable, but this is speculative due to the lack of comprehensive data.

Answer - {""Survival"": ""True""}"
21,"The pathology report provides the following key details:

1. **Tumor Characteristics**: The adenocarcinoma is moderately differentiated and measures 2.5 cm. Moderately differentiated tumors generally have a better prognosis than poorly differentiated ones.

2. **Margins**: The surgical margins are negative, indicating that the tumor has been completely excised with no cancerous cells at the edges of the removed tissue.

3. **Vascular and Lymphatic Invasion**: There is no evidence of vascular or lymphatic invasion, which is a positive prognostic factor as it suggests the cancer has not spread through these pathways.

4. **Lymph Nodes**: All examined regional lymph nodes (five in total) are negative for malignancy, indicating no regional lymph node metastasis.

5. **Pleural Invasion**: The tumor shows invasion towards the pleural surface but does not directly involve the visceral pleura. This suggests limited pleural involvement, which is less concerning than direct invasion.

Overall, the report indicates a localized tumor with no evidence of spread to lymph nodes or distant sites, and negative surgical margins. These factors generally suggest a favorable prognosis and a higher likelihood of survival beyond 2.48 years.

Answer - {""Survival"": ""True""}"
22,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key findings:

1. **Metastatic Carcinoma in Multiple Lymph Nodes**: The presence of metastatic carcinoma in multiple lymph nodes indicates that the cancer has spread beyond the primary site. This is generally associated with a poorer prognosis.

2. **Poorly Differentiated Adenocarcinoma**: Poor differentiation in adenocarcinoma suggests a more aggressive tumor, which typically correlates with a worse prognosis.

3. **Tumor Size**: The primary tumor size is 1.7 cm, which is relatively small. However, the size is less significant in this context due to the presence of metastasis.

4. **Capsular Penetration and Lymphatic Invasion**: These findings indicate aggressive behavior of the tumor, further suggesting a poor prognosis.

5. **Negative Surgical Margins**: While the surgical margins are negative, indicating that the tumor was completely resected at the primary site, the presence of metastatic disease in lymph nodes is a more critical factor in determining prognosis.

6. **Exclusion of Breast Carcinoma**: The exclusion of breast carcinoma as the source of metastasis confirms the pulmonary origin, which is consistent with the diagnosis of lung cancer.

Given these findings, particularly the metastatic spread to multiple lymph nodes and the poorly differentiated nature of the tumor, the prognosis is poor. Therefore, the likelihood of survival after 2.48 years is low.

Answer - {""Survival"": ""False""}"
23,"The pathology report provides the following key details:

1. **Lymph Nodes**: All excised lymph nodes, including those at levels IX and XI, are negative for malignancy. This indicates no lymph node metastasis.

2. **Tumor Characteristics**: The tumor is a moderately differentiated adenocarcinoma, measuring 2.0 cm. Moderately differentiated tumors generally have a better prognosis than poorly differentiated ones.

3. **Surgical Margins**: The surgical margins are clear, meaning the tumor was completely excised with no residual cancerous tissue at the edges of the resected specimen.

4. **Pleural Involvement**: There is no pleural involvement, which is a positive prognostic factor as pleural invasion can indicate a more advanced disease.

5. **Overall Findings**: The findings suggest a localized lung adenocarcinoma with no evidence of metastasis in the examined lymph nodes.

Given these factors, the prognosis for survival beyond 2.48 years is favorable. The absence of lymph node involvement, clear surgical margins, and lack of pleural invasion all contribute to a positive outlook.

Answer - {""Survival"": ""True""}"
24,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key details:

1. **Tumor Size and Location**: The tumor is located in the left upper lobe of the lung and measures 6.5 x 6.5 x 5.0 cm. This size classifies it as pT2b, indicating a larger tumor but not the largest category.

2. **Lymph Node Involvement**: The classification pN1 (6/28) indicates that there is regional lymph node involvement, with 6 out of 28 lymph nodes showing metastasis. Lymph node involvement generally suggests a more advanced disease and can negatively impact prognosis.

3. **Metastasis**: The classification pMx indicates that distant metastasis cannot be assessed. This leaves some uncertainty regarding the spread of the disease beyond regional lymph nodes.

4. **Tumor Grade**: The tumor is graded as G3, which means it is poorly differentiated. Poorly differentiated tumors tend to have a worse prognosis due to their aggressive nature.

5. **Immunohistochemical Analysis**: The tumor cells are positive for CK7, which is common in lung adenocarcinomas. The Ki-67 proliferation index is 40%, indicating a relatively high rate of cell proliferation, which can be associated with a more aggressive tumor and potentially poorer prognosis.

Considering these factors:
- The presence of lymph node involvement (pN1) and a high Ki-67 index suggest a more aggressive disease.
- The tumor is poorly differentiated (G3), which is typically associated with a worse prognosis.
- The lack of visceral pleura infiltration is a positive aspect, but the other factors weigh more heavily towards a poorer prognosis.

Based on these considerations, the likelihood of survival after 2.48 years is less favorable.

Answer - {""Survival"": ""False""}"
25,"1. **Diagnosis and Tumor Characteristics**: The patient has metastatic adenocarcinoma, which indicates that the cancer has spread beyond the primary site. The tumor is moderately to poorly differentiated, which generally suggests a more aggressive cancer.

2. **Lymph Node Involvement**: Eight out of twelve lymph nodes from the left lung are positive for cancer, and additional lymph nodes are affected. This extensive lymph node involvement is a poor prognostic factor.

3. **Lymphovascular Invasion**: The presence of lymphovascular invasion indicates that the cancer has the potential to spread through the lymphatic system and blood vessels, further worsening the prognosis.

4. **Direct Extension**: The tumor has direct extension into two intraparenchymal lymph nodes, suggesting aggressive local spread.

5. **Molecular Analysis**: No EGFR mutations were detected, which may limit the effectiveness of certain targeted therapies. The presence of a polymorphism of uncertain clinical significance does not provide clear prognostic information.

6. **Overall Assessment**: Given the metastatic nature of the adenocarcinoma, extensive lymph node involvement, lymphovascular invasion, and lack of EGFR mutations, the prognosis is poor. These factors collectively suggest a lower likelihood of survival beyond 2.48 years.

Answer - {""Survival"": ""False""}"
26,"1. **Tumor Characteristics**: The invasive adenocarcinoma is classified as histologic grade 2/4, which indicates a moderately differentiated tumor. The tumor size is 3.5 cm, which is relatively small.

2. **Lymph Node Involvement**: The report mentions that the majority of lymph nodes show no tumor presence, except for hilar node #2, which contains metastatic adenocarcinoma. This indicates some lymph node involvement, which is a negative prognostic factor.

3. **Visceral Pleura and Vascular Invasion**: There is no invasion of the visceral pleura or large vessels, which is a positive factor as it suggests the tumor has not spread extensively.

4. **TNM Staging**: The TNM stage is pT2a, pN1, pMX. The pT2a indicates a tumor size between 3 and 5 cm without invasion into the visceral pleura or main bronchus. The pN1 indicates regional lymph node involvement, which is a concern for potential spread. The pMX indicates that distant metastasis cannot be assessed.

5. **Resection Margins**: The resection margins are clear of the tumor, which is a positive factor as it suggests that the tumor was completely removed during surgery.

6. **Overall Prognosis**: The presence of metastatic adenocarcinoma in one lymph node (pN1) is a concern, but the clear resection margins and lack of visceral pleura or vascular invasion are positive factors. The moderately differentiated grade and small tumor size also contribute positively. However, the lymph node involvement does pose a risk for recurrence or spread.

Based on these factors, the prognosis is somewhat mixed, but there are several positive indicators that suggest a reasonable chance of survival beyond 2.48 years, despite the lymph node involvement.

Answer - {""Survival"": ""True""}"
27,"1. **Tumor Characteristics**: The adenocarcinoma is located in the left upper lobe of the lung and measures 3.5 x 2.8 x 2.5 cm. It includes components of solid, acinar, and bronchioloalveolar cell carcinoma. The tumor invades the visceral pleura, which can be a negative prognostic factor.

2. **Metastasis**: There is evidence of metastatic adenocarcinoma in the peribronchial lymph nodes. This indicates that the cancer has spread beyond the primary tumor site, which generally worsens the prognosis.

3. **Lymphatic and Vascular Invasion**: While there is no vascular invasion, lymphatic invasion is still pending. The presence of lymphatic invasion could further negatively impact the prognosis.

4. **Additional Findings**: The report mentions centrilobular emphysema, pulmonary hemosiderosis, and necrotizing granulomas in the lymph nodes. These findings may complicate the clinical picture but are not directly indicative of the cancer's aggressiveness or spread.

5. **Lymph Node Involvement**: Some lymph nodes are negative for neoplasm, which is a positive finding, but the presence of metastatic adenocarcinoma in peribronchial lymph nodes is concerning.

6. **Overall Assessment**: The presence of metastatic adenocarcinoma in lymph nodes and pleural invasion suggests a more advanced stage of cancer, which typically correlates with a poorer prognosis. The pending lymphatic invasion results could further influence this assessment.

Based on the information provided, the presence of metastatic disease in lymph nodes and pleural invasion suggests a lower likelihood of survival beyond 2.48 years.

Answer - {""Survival"": ""False""}"
28,"The pathology report describes a cavitated poorly differentiated adenocarcinoma in the right upper lobe of the lung, measuring 58 mm. Key findings include:

1. **Visceral Pleural Invasion and Chest Wall Involvement**: The tumor has invaded the visceral pleura and involves the chest wall, which indicates a more advanced local disease.

2. **Clear Bronchial Resection Margin**: The bronchial resection margin is clear, suggesting that the surgical removal of the tumor was complete in that area.

3. **Blood Vessel Invasion**: There is evidence of blood vessel invasion, which is a negative prognostic factor as it may facilitate hematogenous spread of the cancer.

4. **No Lymphatic or Perineural Invasion**: The absence of lymphatic and perineural invasion is a positive finding, as these types of invasions can lead to further spread of the disease.

5. **No Lymph Node Metastases**: No metastases were found in the lymph nodes, which is a favorable prognostic factor.

6. **No Residual Malignancy in Chest Wall Tissues or Rib Bone**: This suggests that the surgical resection was successful in removing the tumor from these areas.

Considering these factors, the presence of blood vessel invasion and chest wall involvement are concerning for potential spread and recurrence, which negatively impacts prognosis. However, the absence of lymph node metastases and clear surgical margins are positive factors. Given the balance of these findings, the prognosis is uncertain, but the presence of blood vessel invasion and chest wall involvement suggests a higher risk of poor outcome.

Answer - {""Survival"": ""False""}"
29,"To determine the likelihood of survival after 2.48 years based on the pathology report, let's analyze the key details:

1. **Tumor Differentiation**: The tumor is described as poorly differentiated adenocarcinoma. Poor differentiation generally indicates a more aggressive tumor, which can be associated with a worse prognosis.

2. **Tumor Size**: The tumor measures 3.5 x 3 cm. While not very large, the size alone does not provide a complete picture of prognosis without considering other factors.

3. **Venous Invasion**: There is no evidence of venous invasion, which is a positive factor as venous invasion can facilitate metastasis.

4. **Lymph Node Involvement**: Seven hilar lymph nodes were examined, and all showed reactive changes but were negative for metastasis. The absence of lymph node metastasis is a favorable prognostic factor.

5. **Surgical Margins**: The surgical margins are uninvolved, indicating that the tumor was completely resected, which is another positive factor for prognosis.

Considering these factors, the absence of lymph node metastasis, no venous invasion, and complete resection with uninvolved margins are all favorable indicators. Despite the poor differentiation, these positive factors suggest a reasonable likelihood of survival beyond 2.48 years.

Answer - {""Survival"": ""True""}"
30,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key details:

1. **Tumor Characteristics**: The report describes a solid predominant adenocarcinoma measuring 3.7 cm. The tumor is classified as Stage IIB. Stage IIB typically indicates a larger tumor or one that has spread to nearby structures but not to distant sites.

2. **Lymph Node Involvement**: All 11 examined lymph nodes are negative for cancer, which is a favorable prognostic factor as it suggests no regional lymph node metastasis.

3. **Invasion**: There is no visceral pleural invasion or lymph-vascular invasion identified. The absence of these invasions is generally associated with a better prognosis.

4. **Molecular Studies**: No EGFR mutations were detected. While the absence of EGFR mutations may limit certain targeted therapies, it does not directly correlate with a poor prognosis.

5. **Overall Staging and Prognosis**: Stage IIB lung cancer indicates a localized disease with a relatively better prognosis compared to more advanced stages. The absence of lymph node involvement and lack of invasion into critical structures further supports a more favorable outcome.

Based on these factors, the patient has a localized tumor with no lymph node involvement or significant invasive features, which generally suggests a higher likelihood of survival beyond 2.48 years.

Answer - {""Survival"": ""True""}"
31,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key findings:

1. **Diagnosis and Tumor Characteristics**:
   - The patient has a non-small cell carcinoma, specifically a poorly differentiated adenocarcinoma, located in the right lower lobe of the lung.
   - The tumor size is 3.5 cm, which is relatively small.

2. **Invasion**:
   - There is evidence of invasion into the visceral pleura and large vessels. This indicates a more aggressive tumor behavior and potential for spread.

3. **Lymph Node Involvement**:
   - Metastases are present in the ipsilateral peribronchial and hilar lymph nodes. This suggests regional spread of the cancer, which is a negative prognostic factor.
   - However, multiple lymph node biopsies from various stations were negative for malignancy, indicating that the spread might be limited to certain regional nodes.

4. **Margins**:
   - The bronchial margins are free of tumor, with a 5 mm distance from the invasive carcinoma to the closest margin. This is a positive finding, as it suggests that the tumor was completely resected with clear margins.

5. **Overall Staging and Prognosis**:
   - The presence of lymph node metastases and invasion into visceral pleura and large vessels suggests a more advanced stage of cancer, likely stage III.
   - Poor differentiation of the adenocarcinoma also indicates a more aggressive tumor with a poorer prognosis.

Considering these factors, the presence of lymph node metastases and invasion into critical structures like the visceral pleura and large vessels are significant negative prognostic indicators. Despite the clear surgical margins, the overall prognosis is likely poor, and survival beyond 2.48 years is uncertain.

Answer - {""Survival"": ""False""}"
32,"To determine the likelihood of survival after 2.48 years based on the pathology report, let's analyze the key findings:

1. **Tumor Characteristics**: The report describes a poorly differentiated adenocarcinoma measuring 2.5 cm. Poor differentiation generally indicates a more aggressive tumor, which can be associated with a worse prognosis.

2. **Surgical Margins**: The surgical margins are uninvolved, which is a positive factor as it suggests that the tumor was completely resected.

3. **Visceral Pleural Invasion**: There is a suggestion of visceral pleural invasion. Pleural invasion can be associated with a higher stage of cancer and potentially a worse prognosis.

4. **Lymph Node Involvement**: 
   - The right lower lobe lobectomy showed no residual malignancy, and two lymph nodes from this specimen were negative for metastatic disease.
   - Among the examined lymph nodes, only the level 12 nodes demonstrated evidence of metastasis, while other levels showed no metastatic involvement. The presence of metastasis in any lymph node indicates a spread of the disease, which can negatively impact prognosis.

5. **Overall Staging and Prognosis**: The presence of poorly differentiated adenocarcinoma with lymph node metastasis (even if limited to level 12) and possible pleural invasion suggests a more advanced disease. However, the complete resection with uninvolved margins and limited lymph node involvement may still offer a chance for survival beyond 2.48 years, depending on additional treatments and individual patient factors.

Considering these factors, the prognosis is guarded but not definitively poor. The presence of metastasis in lymph nodes and possible pleural invasion are concerning, but the uninvolved surgical margins and limited lymph node involvement provide some positive aspects.

Based on the information provided, the likelihood of survival beyond 2.48 years is uncertain but possible. Therefore, the most appropriate choice is:

Answer - {""Survival"": ""True""}"
33,"To determine the likelihood of survival after 2.48 years based on the pathology report, let's analyze the key findings:

1. **Tumor Characteristics**: The tumor is a poorly differentiated adenocarcinoma, which generally indicates a more aggressive cancer with a potentially worse prognosis compared to well-differentiated tumors.

2. **Size and Location**: The tumor measures 3.5 cm and is located in the left upper lobe of the lung. The size is relatively small, which is a favorable factor.

3. **Pleural Invasion**: The tumor invades the pleura, which can be associated with a higher risk of recurrence and a worse prognosis.

4. **Surgical Margins**: The surgical margins are negative for tumor, indicating that the tumor was completely resected, which is a positive prognostic factor.

5. **Vascular Invasion**: The presence of vascular invasion is a negative prognostic factor as it suggests a higher likelihood of metastasis and recurrence.

6. **Lymph Node Involvement**: There is no evidence of regional lymph node involvement, which is a favorable factor as lymph node metastasis is associated with a worse prognosis.

7. **Distant Metastasis**: There is no evidence of distant metastasis, which is a positive factor for survival.

Considering these factors, the presence of vascular invasion and pleural invasion are concerning and suggest a higher risk of recurrence and metastasis. However, the absence of lymph node involvement and distant metastasis, along with negative surgical margins, are positive factors. Given the mixed prognostic indicators, the likelihood of survival beyond 2.48 years is uncertain, but the presence of vascular invasion and pleural invasion may tilt the balance towards a less favorable outcome.

Answer - {""Survival"": ""False""}"
34,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key findings:

1. **Tumor Characteristics**: The report describes a 2.8 cm invasive moderately differentiated adenocarcinoma. Moderate differentiation generally indicates an intermediate prognosis compared to well-differentiated (better prognosis) and poorly differentiated (worse prognosis) tumors.

2. **Invasion**: There is angiolymphatic and visceral pleural invasion. Angiolymphatic invasion can be a negative prognostic factor as it suggests potential for metastasis. Visceral pleural invasion also indicates a more aggressive tumor behavior.

3. **Lymph Nodes**: All sampled lymph nodes are benign, indicating no regional lymph node metastasis. This is a positive prognostic factor, as lymph node involvement often correlates with a worse prognosis.

4. **Surgical Margins**: The surgical resection margins are free of tumor, which is a favorable finding as it suggests complete resection of the tumor.

5. **Pathologic Stage**: The tumor is staged as T2N0MX. T2 indicates a tumor size greater than 3 cm but less than 5 cm or involvement of the main bronchus or visceral pleura. N0 indicates no regional lymph node metastasis. MX means distant metastasis cannot be assessed. The absence of lymph node involvement (N0) is a positive factor.

6. **Additional Findings**: Chronic inflammation, submucosal scarring, and emphysematous changes are noted, but these are not directly related to the cancer prognosis.

Considering these factors, the absence of lymph node involvement and clear surgical margins are positive indicators for survival. However, the presence of angiolymphatic and visceral pleural invasion suggests a more aggressive tumor. Overall, the prognosis is mixed, but the absence of lymph node involvement and clear margins are significant positive factors.

Based on this analysis, the likelihood of survival after 2.48 years is more favorable than not, despite the aggressive features.

Answer - {""Survival"": ""True""}"
35,"To determine the likelihood of survival after 2.48 years based on the provided pathology report, let's analyze the key details:

1. **Diagnosis**: The patient has a poorly differentiated non-small cell carcinoma, specifically adenocarcinoma, originating from the lung. Poor differentiation generally indicates a more aggressive tumor, which can be associated with a worse prognosis.

2. **Tumor Size and Unifocality**: The tumor measures 5.5 x 5.0 cm and is unifocal. While the size is relatively large, the fact that it is unifocal (single tumor) is somewhat favorable compared to multifocal disease.

3. **Lymph Node Involvement**: All examined lymph nodes are negative for carcinoma. The absence of lymph node metastasis is a positive prognostic factor, as lymph node involvement often indicates a higher stage and worse prognosis.

4. **Immunohistochemical Staining**: The tumor is positive for TTF-1 and negative for p63, CK5/6, CK7, and CK20, supporting the diagnosis of adenocarcinoma. TTF-1 positivity is typical for lung adenocarcinomas and helps rule out other types of cancer.

5. **Pending Further Characterization**: Additional immunoevaluation is pending, which may provide more insights into the tumor's behavior and potential treatment options.

Considering these factors, the absence of lymph node involvement is a significant positive indicator for survival. Although the tumor is poorly differentiated, which is a negative factor, the lack of metastatic spread to lymph nodes suggests a localized disease, which generally has a better prognosis.

Based on the information provided, the likelihood of survival after 2.48 years is more favorable, given the absence of lymph node metastasis and the unifocal nature of the tumor.

Answer - {""Survival"": ""True""}"
36,"To determine if the patient will survive after 2.48 years based on the provided pathology report, let's analyze the key findings:

1. **Tumor Characteristics**: The report describes a poorly differentiated adenocarcinoma with clear cell changes, measuring 7 cm. Poor differentiation generally indicates a more aggressive tumor, but the size alone does not determine prognosis.

2. **Visceral Pleura Invasion**: There is no invasion of the visceral pleura, which is a positive prognostic factor as pleural invasion can indicate a more advanced disease.

3. **Margins**: The bronchial and vascular margins are negative, meaning the tumor was completely resected with no residual cancer at the surgical margins. This is a favorable finding.

4. **Lymph Nodes**: All examined lymph nodes from levels 4, 7, and 9 show no evidence of tumor. The absence of lymph node involvement is a significant positive prognostic factor, as lymph node metastasis is associated with a worse prognosis.

5. **Sixth Rib**: The portion of the sixth rib examined also showed no evidence of tumor, indicating no local spread to the rib.

6. **Overall Findings**: The report suggests a successful resection of the lung cancer with clear margins and no metastatic spread to the sampled lymph nodes. This generally indicates a localized disease with a good chance of survival beyond 2.48 years, assuming no other complicating factors.

Based on these findings, the prognosis appears favorable, and the patient is likely to survive beyond 2.48 years.

Answer - {""Survival"": ""True""}"
37,"The pathology report provides the following key information:

1. **Tumor Type and Size**: The tumor is a mixed acinar and bronchioloalveolar adenocarcinoma measuring 3.5 cm, with moderate to poorly differentiated histology. Poor differentiation generally indicates a more aggressive tumor.

2. **Lymph Node Involvement**: Metastatic adenocarcinoma was found in one of two resected lymph nodes. Lymph node involvement is a significant factor in cancer staging and prognosis, often indicating a higher stage and a worse prognosis.

3. **KRAS Mutation**: The presence of a KRAS mutation, particularly in codon 12 or 13, is associated with a poorer prognosis and potential resistance to certain therapies, such as EGFR inhibitors.

4. **Other Lymph Nodes and Tissue**: The remaining lymph nodes and associated fibroadipose tissue were negative for tumor, which is a positive finding, but the presence of metastasis in one lymph node is concerning.

Considering these factors, the presence of lymph node metastasis and a KRAS mutation suggests a more aggressive disease with a poorer prognosis. While the tumor size is relatively small, the combination of poor differentiation, lymph node involvement, and KRAS mutation typically indicates a higher risk of recurrence and lower survival rates.

Based on this analysis, the likelihood of survival after 2.48 years is lower, leading to the conclusion:

Answer - {""Survival"": ""False""}"
